Amedeo Smart

Free Medical Literature Service

 

Amedeo

Vaccines
  Free Subscription

Articles published in
J Virol
    October 2025
  1. PAN Z, Jiang L, Chen Y, Peng H, et al
    Adjuvant-dependent protection of SARS-CoV-2 spike vaccines: comparative immunogenicity of human-applicable formulations.
    J Virol. 2025 Oct 3:e0109925. doi: 10.1128/jvi.01099.
    >> Share

    September 2025
  2. SUN L, Huang M, Feng S, Zhang W, et al
    Developing an eVLP mRNA vaccine for respiratory syncytial virus with enhanced pre-fusion targeting humoral responses.
    J Virol. 2025 Sep 30:e0120925. doi: 10.1128/jvi.01209.
    >> Share

  3. ZHOU J, Cai S, Huang H, Yang F, et al
    LPS/TLR4-activated M1-polarized macrophage-derived exosomes enhance IBV vaccine efficacy in chickens.
    J Virol. 2025 Sep 23:e0115625. doi: 10.1128/jvi.01156.
    >> Share

  4. PENG G, Zhao X, Zou X, Zhang H, et al
    An attenuated African swine fever virus with deletions of the CD2v and A137R genes offers complete protection against homologous challenge in pigs.
    J Virol. 2025;99:e0026225.
    >> Share

  5. QU Y, Li J, Deng H, Wang Y, et al
    Viroporins: emerging viral infection mechanisms and therapeutic targets.
    J Virol. 2025;99:e0103825.
    >> Share

  6. PAPPAS C, Brock N, Belser JA, Kieran TJ, et al
    Identification of clinical and virological correlates associated with influenza A candidate vaccine virus (CVV) attenuation in a ferret model.
    J Virol. 2025 Sep 17:e0102325. doi: 10.1128/jvi.01023.
    >> Share

  7. CAO M, Li Y, Song X, Lu Z, et al
    Broad-spectrum vaccines against various and evolving viruses: from antigen design to nanoparticle delivery.
    J Virol. 2025 Sep 12:e0099725. doi: 10.1128/jvi.00997.
    >> Share

  8. FAN W, Zeng X, Chen Y, Yu Q, et al
    A recombinant Marek's disease vaccine candidate provides complete protection against infectious bursal disease virus and H9 subtype avian influenza virus in chickens.
    J Virol. 2025 Sep 11:e0114925. doi: 10.1128/jvi.01149.
    >> Share

  9. HAGA Y, Babu E P, Swiderska-Syn M, Reagan EK, et al
    Hepatitis C virus modified (S)E2(F442NYT)-mRNA-LNP candidate vaccine promotes helper CXCR5(+)T cells.
    J Virol. 2025 Sep 5:e0135525. doi: 10.1128/jvi.01355.
    >> Share

  10. OOM AL, Wilson KK, Yonatan M, Rettig S, et al
    Correction for Oom et al., "The two-dose MVA-BN mpox vaccine induces a nondurable and low avidity MPXV-specific antibody response".
    J Virol. 2025 Sep 4:e0087225. doi: 10.1128/jvi.00872.
    >> Share

    August 2025
  11. CHATURBHUJ DN, Sliepen K, Cupo A, Steinberg B, et al
    A modification to heptad repeat 1 of gp41 improves yield and/or quality of soluble pre-fusion HIV-1 envelope glycoprotein trimers.
    J Virol. 2025 Aug 27:e0091325. doi: 10.1128/jvi.00913.
    >> Share

  12. HU Z, Tian S, Zhou Y, Wang Y, et al
    Nanoparticle vaccine based on the pre-fusion F glycoprotein of respiratory syncytial virus elicits robust protective immune responses.
    J Virol. 2025 Aug 26:e0090325. doi: 10.1128/jvi.00903.
    >> Share

  13. HE Q, Zou Y, Yu B, Yuan Q, et al
    A novel nanoparticle vaccine, based on S1-CTD, elicits robust protective immune responses against porcine deltacoronavirus.
    J Virol. 2025 Aug 21:e0067425. doi: 10.1128/jvi.00674.
    >> Share

  14. LIU J, Xia Y, Tian C, Chen Z, et al
    E2-based mRNA vaccine encapsulated in lipid nanoparticles protects pigs against classical swine fever virus.
    J Virol. 2025 Aug 21:e0097825. doi: 10.1128/jvi.00978.
    >> Share

  15. ZHANG H, Deng X, Dai R, Fu J, et al
    Inadequate immune response to inactivated COVID-19 vaccine among older people living with HIV: a prospective cohort study.
    J Virol. 2025 Aug 21:e0068825. doi: 10.1128/jvi.00688.
    >> Share

  16. HU J, Zheng H, Ran W, Wang X, et al
    Mucosal vaccination with long-form TSLP induces migratory cDC1-mediated adaptive immunity against SARS-CoV-2 infection.
    J Virol. 2025 Aug 19:e0123125. doi: 10.1128/jvi.01231.
    >> Share

  17. ZHANG C, Zhou Y-C, Song W-Y, Liu X-X, et al
    Rationally designed self-assembled peptide nanofibers provoke robust humoral immunity against nervous necrosis virus.
    J Virol. 2025;99:e0031925.
    >> Share

  18. CHIU H-J, Wang H-C, Chang W
    Structural dissection of vaccinia G9 identifies residues essential for membrane fusion and complex assembly.
    J Virol. 2025 Aug 18:e0072325. doi: 10.1128/jvi.00723.
    >> Share

  19. GUO S, Ru Y, Zhang H, Xue J, et al
    An African swine fever virus-specific antibody reactome reveals antigens as potential candidates for vaccine development.
    J Virol. 2025 Aug 14:e0047825. doi: 10.1128/jvi.00478.
    >> Share

  20. DZIMIANSKI JV, Nagashima KA, Cruz JM, Sautto GA, et al
    Assessing the structural boundaries of broadly reactive antibody interactions with diverse H3 influenza hemagglutinin proteins.
    J Virol. 2025 Aug 14:e0045325. doi: 10.1128/jvi.00453.
    >> Share

  21. SOWNTHIRARAJAN B, Mason M, Loganathan G, Manivasagam S, et al
    A versatile H5N1-VSV platform for safe influenza virus research applications.
    J Virol. 2025 Aug 8:e0097525. doi: 10.1128/jvi.00975.
    >> Share

  22. YU R, Bai Y, Zhang L, Zhou P, et al
    Single self-cleaving mRNA vaccine expressing multiple viral structural proteins elicits robust immune responses and protects nursing piglets against PDCoV infection.
    J Virol. 2025 Aug 6:e0084925. doi: 10.1128/jvi.00849.
    >> Share

  23. BAI Y-Z, Xu H, Liu Y-G, Sun Y, et al
    Nsp2 replicase-mediated viral uncoating in porcine alveolar macrophages contributes to the attenuation of PRRSV-2 live attenuated vaccine.
    J Virol. 2025 Aug 4:e0063625. doi: 10.1128/jvi.00636.
    >> Share

  24. MBOKO WP, Wang Y, Cao W, Sayedahmed EE, et al
    Trained ILCs confer adaptive immunity-independent protection against influenza.
    J Virol. 2025 Aug 4:e0053225. doi: 10.1128/jvi.00532.
    >> Share

    July 2025
  25. DONG J, Yue Luo S, Smyth S, Melvie G, et al
    The vaccinia virus protein, C16, promotes the ubiquitylation and relocalization of the antiviral E3 ubiquitin-ligase, TRIM25.
    J Virol. 2025 Jul 28:e0089825. doi: 10.1128/jvi.00898.
    >> Share

  26. TOHMA K, Ford-Siltz LA, Kendra JA, Parra GI, et al
    Manipulation of immunodominant variable epitopes of norovirus capsid protein elicited cross-blocking antibodies to different GII.4 variants despite the low potency of the polyclonal sera.
    J Virol. 2025;99:e0061125.
    >> Share

  27. LEONARD RA, Spurrier MA, Skavicus S, Luo Z, et al
    Development of DNA and mRNA-LNP vaccines against an H5N1 clade 2.3.4.4b influenza virus.
    J Virol. 2025 Jul 16:e0079525. doi: 10.1128/jvi.00795.
    >> Share

  28. CARLOCK MA, Pierce SR, Ross TM
    Breadth of antibody activity elicited by an influenza B hemagglutinin vaccine is influenced by pre-existing immune responses to influenza B viruses.
    J Virol. 2025 Jul 15:e0070525. doi: 10.1128/jvi.00705.
    >> Share

  29. WINSTON SM, Wiggins KB, Schultz-Cherry S, Davidoff AM, et al
    Teaching an old vector new tricks: the surprising versatility of AAV vaccines.
    J Virol. 2025 Jul 14:e0073025. doi: 10.1128/jvi.00730.
    >> Share

  30. HENG W, Zang D, Li R, Jiang Q, et al
    A novel replication-deficient FCV vaccine provides strong immune protection in cats.
    J Virol. 2025 Jul 8:e0009325. doi: 10.1128/jvi.00093.
    >> Share

    June 2025
  31. SONG Q, Yang H, Zhu H, Hu Y, et al
    Hydrophobic residue substitutions enhance the stability and in vivo immunogenicity of respiratory syncytial virus fusion protein.
    J Virol. 2025;99:e0008725.
    >> Share

  32. HARRIS C, Kapingidza AB, San JE, Christopher J, et al
    Design of SARS-CoV-2 RBD immunogens to focus immune responses toward conserved coronavirus epitopes.
    J Virol. 2025 Jun 13:e0046525. doi: 10.1128/jvi.00465.
    >> Share

  33. LIU M, Aryal B, Niu X, Wang Q, et al
    Engineering a recombination-resistant live attenuated vaccine candidate with suppressed interferon antagonists for PEDV.
    J Virol. 2025 Jun 12:e0045125. doi: 10.1128/jvi.00451.
    >> Share

  34. SCHLEISS MR, Fernandez-Alarcon C, Bierle CJ, Geballe AP, et al
    Replication-deficient whole-virus vaccines against cytomegalovirus induce protective immunity in a guinea pig congenital infection model.
    J Virol. 2025 Jun 11:e0020725. doi: 10.1128/jvi.00207.
    >> Share

  35. COGGON A, Lopes S, Simon G, Arendsee Z, et al
    Quantifying the zoonotic risk profile of European influenza A viruses in swine from 2010 to 2020 inclusive.
    J Virol. 2025 Jun 4:e0030625. doi: 10.1128/jvi.00306.
    >> Share

    May 2025
  36. KARTHIGEYAN KP, Connors M, Binuya CR, Gross M, et al
    A human cytomegalovirus prefusion-like glycoprotein B subunit vaccine elicits humoral immunity similar to that of postfusion gB in mice.
    J Virol. 2025 May 8:e0217824. doi: 10.1128/jvi.02178.
    >> Share

  37. LUGANO D, Mwangi K, Mware B, Kibet G, et al
    Characterization of SARS-CoV-2 intrahost genetic evolution in vaccinated and non-vaccinated patients from the Kenyan population.
    J Virol. 2025 May 6:e0048225. doi: 10.1128/jvi.00482.
    >> Share

    April 2025
  38. LE CTT, Kim K-H, Raha JR, Bhatnagar N, et al
    Dual roles of influenza B virus neuraminidase mRNA vaccine in enhancing cross-lineage protection by supplementing inactivated split vaccination.
    J Virol. 2025 Apr 23:e0229424. doi: 10.1128/jvi.02294.
    >> Share

  39. LI Y, Yang S, Qian J, Liu S, et al
    Molecular characteristics of the immune escape of coronavirus PEDV under the pressure of vaccine immunity.
    J Virol. 2025 Apr 16:e0219324. doi: 10.1128/jvi.02193.
    >> Share

  40. THIONO DJ, Samaras D, Phan TTN, Zhu DR, et al
    Stabilized dengue virus 2 envelope subunit vaccine redirects the neutralizing antibody response to all E-domains.
    J Virol. 2025 Apr 16:e0022925. doi: 10.1128/jvi.00229.
    >> Share

  41. KAWAKITA T, Sekiya T, Kameda Y, Nomura N, et al
    ARNAX is an ideal adjuvant for COVID-19 vaccines to enhance antigen-specific CD4(+) and CD8(+) T-cell responses and neutralizing antibody induction.
    J Virol. 2025 Apr 15:e0229024. doi: 10.1128/jvi.02290.
    >> Share

  42. LOU Y-N, Sun M-X, Li K, Xiong X-C, et al
    A single residue in domain II of envelope protein of yellow fever virus is critical for neutralization sensitivity.
    J Virol. 2025;99:e0177024.
    >> Share

  43. CHENTOUFI AA, Prakash S, Vahed H, Karan S, et al
    A tissue-targeted prime/pull/keep therapeutic herpes simplex virus vaccine protects against recurrent ocular herpes infection and disease in HLA-A*0201 transgenic rabbits.
    J Virol. 2025 Apr 10:e0013525. doi: 10.1128/jvi.00135.
    >> Share

    March 2025
  44. BLASS E, Colarusso A, Aid M, Larocca RA, et al
    Early spatiotemporal evolution of the immune response elicited by adenovirus serotype 26 vector vaccination in mice.
    J Virol. 2025 Mar 31:e0024725. doi: 10.1128/jvi.00247.
    >> Share

  45. OOM AL, Wilson KK, Yonatan M, Rettig S, et al
    The two-dose MVA-BN mpox vaccine induces a nondurable and low avidity MPXV-specific antibody response.
    J Virol. 2025 Mar 31:e0025325. doi: 10.1128/jvi.00253.
    >> Share

  46. JANA ID, Kanjo K, Roy S, Bhasin M, et al
    Early 2022 breakthrough infection sera from India target the conserved cryptic class 5 epitope to counteract immune escape by SARS-CoV-2 variants.
    J Virol. 2025 Mar 26:e0005125. doi: 10.1128/jvi.00051.
    >> Share

  47. LI P, Faraone JN, Hsu CC, Chamblee M, et al
    Role of glycosylation mutations at the N-terminal domain of SARS-CoV-2 XEC variant in immune evasion, cell-cell fusion, and spike stability.
    J Virol. 2025 Mar 26:e0024225. doi: 10.1128/jvi.00242.
    >> Share

  48. BEAVIS AC, Xiao P, Gingerich MC, Briggs K, et al
    A parainfluenza virus 5 (PIV5)-vectored intranasal SARS-CoV-2 vaccine (CVXGA1) elicits protective and long-lasting immunity in nonhuman primates.
    J Virol. 2025 Mar 21:e0199024. doi: 10.1128/jvi.01990.
    >> Share

  49. BEAVIS AC, Li Z, Briggs K, Gingerich MC, et al
    Efficacy of parainfluenza virus 5 (PIV5)-vectored intranasal COVID-19 vaccine as a single dose primer and booster against SARS-CoV-2 variants.
    J Virol. 2025 Mar 21:e0198924. doi: 10.1128/jvi.01989.
    >> Share

  50. MLINGO TAM, Theron J, Mokoena NB
    Plasmid DNA-based reverse genetics as a platform for manufacturing of bluetongue vaccine.
    J Virol. 2025 Mar 6:e0013925. doi: 10.1128/jvi.00139.
    >> Share

  51. HU H, Zhang Y, Zheng H, Zhao X, et al
    Thymic stromal lymphopoietin improves protective immunity of the SARS-CoV-2 subunit vaccine by inducing dendritic cell-dependent germinal center response.
    J Virol. 2025 Mar 4:e0232324. doi: 10.1128/jvi.02323.
    >> Share

  52. KARL V, Hofmann M, Thimme R
    Role of antiviral CD8+ T cell immunity to SARS-CoV-2 infection and vaccination.
    J Virol. 2025 Mar 3:e0135024. doi: 10.1128/jvi.01350.
    >> Share

    February 2025
  53. ABBO SR, Yan K, Geertsema C, Hick TAH, et al
    Virus-like particle vaccine with authentic quaternary epitopes protects against Zika virus-induced viremia and testicular damage.
    J Virol. 2025 Feb 27:e0232224. doi: 10.1128/jvi.02322.
    >> Share

  54. KEEP S, Foldes K, Dowgier G, Freimanis G, et al
    Recombinant infectious bronchitis virus containing mutations in non-structural proteins 10, 14, 15, and 16 and within the macrodomain provides complete protection against homologous challenge.
    J Virol. 2025 Feb 27:e0166324. doi: 10.1128/jvi.01663.
    >> Share

  55. LI W, Hangalapura BN, van den Elzen P, van den Born E, et al
    Spike gene variability in porcine epidemic diarrhea virus as a determinant for virulence.
    J Virol. 2025 Feb 26:e0216524. doi: 10.1128/jvi.02165.
    >> Share

  56. CHEN C-X, Wang X, Su W, Tian Y, et al
    Changes in the dynamic characteristics of G-protein can alter the immune-protection efficacy of rabies virus vaccine.
    J Virol. 2025 Feb 21:e0195424. doi: 10.1128/jvi.01954.
    >> Share

  57. PARK H, Kingstad-Bakke B, Cleven T, Jung M, et al
    Diversifying T-cell responses: safeguarding against pandemic influenza with mosaic nucleoprotein.
    J Virol. 2025 Feb 3:e0086724. doi: 10.1128/jvi.00867.
    >> Share

    January 2025
  58. SAMAAN P, Korosec CS, Budylowski P, Chau SLL, et al
    mRNA vaccine-induced SARS-CoV-2 spike-specific IFN-gamma and IL-2 T-cell responses are predictive of serological neutralization and are transiently enhanced by pre-existing cross-reactive immunity.
    J Virol. 2025 Jan 31:e0168524. doi: 10.1128/jvi.01685.
    >> Share

  59. ZHAO B, Sun Z, Wang S, Shi Z, et al
    Structural basis of different neutralization capabilities of monoclonal antibodies against H7N9 virus.
    J Virol. 2025;99:e0140024.
    >> Share

  60. SADLER HL, Rijal P, Tan TK, Townsend ARM, et al
    A locally administered single-cycle influenza vaccine expressing a non-fusogenic stabilized hemagglutinin stimulates strong T-cell and neutralizing antibody immunity.
    J Virol. 2025 Jan 27:e0033124. doi: 10.1128/jvi.00331.
    >> Share

  61. KENNEDY PGE, Grose C
    Insights into pathologic mechanisms occurring during serious adverse events following live zoster vaccination.
    J Virol. 2025 Jan 17:e0181624. doi: 10.1128/jvi.01816.
    >> Share

  62. NAGHIBOSADAT M, Babuadze GG, Pei Y, Hurst J, et al
    Vaccination against SARS-CoV-2 provides low-level cross-protection against common cold coronaviruses in mouse and non-human primate animal models.
    J Virol. 2025 Jan 16:e0139024. doi: 10.1128/jvi.01390.
    >> Share

  63. DSOUZA L, Pant A, Pope B, Yang Z, et al
    Vaccinia growth factor-dependent modulation of the mTORC1-CAD axis upon nutrient restriction.
    J Virol. 2025 Jan 16:e0211024. doi: 10.1128/jvi.02110.
    >> Share

    December 2024
  64. LV H, Teo QW, Lee C-CD, Liang W, et al
    Differential antigenic imprinting effects between influenza H1N1 hemagglutinin and neuraminidase in a mouse model.
    J Virol. 2024 Dec 5:e0169524. doi: 10.1128/jvi.01695.
    >> Share

    November 2024
  65. LI C, Culhane MR, Schroeder DC, Cheeran MC-J, et al
    Quantifying the impact of vaccination on transmission and diversity of influenza A variants in pigs.
    J Virol. 2024 Nov 12:e0124524. doi: 10.1128/jvi.01245.
    >> Share

  66. JIMENEZ-CABELLO L, Utrilla-Trigo S, Rodriguez-Sabando K, Carra-Valenzuela A, et al
    Vaccine candidates based on MVA viral vectors expressing VP2 or VP7 confer full protection against Epizootic hemorrhagic disease virus in IFNAR(-/-) mice.
    J Virol. 2024 Nov 7:e0168724. doi: 10.1128/jvi.01687.
    >> Share

  67. CHEN D, Zhang W, Xiao B, Xu B, et al
    Effect of wild-type vaccine doses on BA.5 hybrid immunity, disease severity, and XBB reinfection risk.
    J Virol. 2024 Nov 5:e0128524. doi: 10.1128/jvi.01285.
    >> Share

  68. DAI W, Xing M, Sun L, Lv L, et al
    Lipid nanoparticles as adjuvant of norovirus VLP vaccine augment cellular and humoral immune responses in a TLR9- and type I IFN-dependent pathway.
    J Virol. 2024 Nov 4:e0169924. doi: 10.1128/jvi.01699.
    >> Share

    October 2024
  69. PANT A, Brahim Belhaouari D, Dsouza L, Yang Z, et al
    Stimulation of neutral lipid synthesis via viral growth factor signaling and ATP citrate lyase during vaccinia virus infection.
    J Virol. 2024 Oct 30:e0110324. doi: 10.1128/jvi.01103.
    >> Share

  70. CAILLAVA AJ, Alfonso V, Tejerina Cibello M, Demaria MA, et al
    A vaccine candidate based on baculovirus displaying chikungunya virus E1-E2 envelope confers protection against challenge in mice.
    J Virol. 2024 Oct 23:e0101724. doi: 10.1128/jvi.01017.
    >> Share

  71. ZHANG D, Xie Y, Liao Q, Jiao Z, et al
    Development of a safe and broad-spectrum attenuated PEDV vaccine candidate by S2 subunit replacement.
    J Virol. 2024 Oct 15:e0042924. doi: 10.1128/jvi.00429.
    >> Share

  72. WANG W, Bhushan G, Paz S, Stauft CB, et al
    Human and hamster sera correlate well in identifying antigenic drift among SARS-CoV-2 variants, including JN.1.
    J Virol. 2024 Oct 4:e0094824. doi: 10.1128/jvi.00948.
    >> Share

  73. DO THT, Wille M, Wheatley AK, Koutsakos M, et al
    Triton X-100-treated virus-based ELLA demonstrates discordant antigenic evolution of influenza B virus hemagglutinin and neuraminidase.
    J Virol. 2024 Oct 3:e0118624. doi: 10.1128/jvi.01186.
    >> Share

    September 2024
  74. HAMELE CE, Luo Z, Leonard RA, Spurrier MA, et al
    Headless hemagglutinin-containing influenza viral particles direct immune responses toward more conserved epitopes.
    J Virol. 2024 Sep 26:e0116624. doi: 10.1128/jvi.01166.
    >> Share

  75. LOES AN, Tarabi RAL, Huddleston J, Touyon L, et al
    High-throughput sequencing-based neutralization assay reveals how repeated vaccinations impact titers to recent human H1N1 influenza strains.
    J Virol. 2024 Sep 24:e0068924. doi: 10.1128/jvi.00689.
    >> Share

  76. SONG X, Li Y, Wang C, Zhao Y, et al
    Efficacy evaluation of a bivalent subunit vaccine against epidemic PEDV heterologous strains with low cross-protection.
    J Virol. 2024 Sep 10:e0130924. doi: 10.1128/jvi.01309.
    >> Share

  77. AGRAWAL P, Knudsen ML, MacCamy A, Hurlburt NK, et al
    Short CDRL1 in intermediate VRC01-like mAbs is not sufficient to overcome key glycan barriers on HIV-1 Env.
    J Virol. 2024 Sep 6:e0074424. doi: 10.1128/jvi.00744.
    >> Share

  78. SOUDANI N, Bricker TL, Darling T, Seehra K, et al
    Immunogenicity and efficacy of XBB.1.5 rS vaccine against the EG.5.1 variant of SARS-CoV-2 in Syrian hamsters.
    J Virol. 2024 Sep 4:e0052824. doi: 10.1128/jvi.00528.
    >> Share

    August 2024
  79. YING B, Liang C-Y, Desai P, Scheaffer SM, et al
    Ipsilateral or contralateral boosting of mice with mRNA vaccines confers equivalent immunity and protection against a SARS-CoV-2 Omicron strain.
    J Virol. 2024 Aug 28:e0057424. doi: 10.1128/jvi.00574.
    >> Share

  80. GOODWIN E, Gibbs JS, Yewdell JW, Eisenlohr LC, et al
    Influenza virus antibodies inhibit antigen-specific de novo B cell responses in mice.
    J Virol. 2024 Aug 28:e0076624. doi: 10.1128/jvi.00766.
    >> Share

  81. WANG G, Verma AK, Guan X, Bu F, et al
    Pan-beta-coronavirus subunit vaccine prevents SARS-CoV-2 Omicron, SARS-CoV, and MERS-CoV challenge.
    J Virol. 2024 Aug 27:e0037624. doi: 10.1128/jvi.00376.
    >> Share

  82. UNO N, Ebensen T, Guzman CA, Ross TM, et al
    Intranasal administration of octavalent next-generation influenza vaccine elicits protective immune responses against seasonal and pre-pandemic viruses.
    J Virol. 2024 Aug 22:e0035424. doi: 10.1128/jvi.00354.
    >> Share

  83. MOSS WJ, Griffin DE
    What's going on with measles?
    J Virol. 2024;98:e0075824.
    >> Share

  84. LI J, Xiao L, Chen Z, Fan L, et al
    A spike-based mRNA vaccine that induces durable and broad protection against porcine deltacoronavirus in piglets.
    J Virol. 2024 Aug 19:e0053524. doi: 10.1128/jvi.00535.
    >> Share

  85. MU Z, Whitley J, Martik D, Sutherland L, et al
    Comparison of the immunogenicity of mRNA-encoded and protein HIV-1 Env-ferritin nanoparticle designs.
    J Virol. 2024 Aug 13:e0013724. doi: 10.1128/jvi.00137.
    >> Share

    July 2024
  86. WIGGINS KB, Winston SM, Reeves IL, Gaevert J, et al
    rAAV expressing a COBRA-designed influenza hemagglutinin generates a protective and durable adaptive immune response with a single dose.
    J Virol. 2024 Jul 30:e0078124. doi: 10.1128/jvi.00781.
    >> Share

  87. NELSON GW, van Duijn J, Yuki Y, Pau MG, et al
    Prediction of differential Gag versus Env responses to a mosaic HIV-1 vaccine regimen by HLA class I alleles.
    J Virol. 2024 Jul 24:e0028124. doi: 10.1128/jvi.00281.
    >> Share

  88. LINGEMANN M, Amaro-Carambot E, Lamirande EW, Pierson TC, et al
    Simultaneous quantitation of neutralizing antibodies against all four dengue virus serotypes using optimized reporter virus particles.
    J Virol. 2024;98:e0068124.
    >> Share

  89. PORTUGAL R, Goldswain H, Moore R, Tully M, et al
    Six adenoviral vectored African swine fever virus genes protect against fatal disease caused by genotype I challenge.
    J Virol. 2024;98:e0062224.
    >> Share

  90. KOTAKI T, Kanai Y, Onishi M, Minami S, et al
    Generation of single-round infectious rotavirus with a mutation in the intermediate capsid protein VP6.
    J Virol. 2024;98:e0076224.
    >> Share

  91. MCMILLEN CM, Megli C, Radisic R, Skvarca LB, et al
    Vaccine strains of Rift Valley fever virus exhibit attenuation at the maternal-fetal placental interface.
    J Virol. 2024 Jul 17:e0098324. doi: 10.1128/jvi.00983.
    >> Share

  92. ZHANG L, Yu R, Wang L, Zhang Z, et al
    Serial cell culture passaging in vitro led to complete attenuation and changes in the characteristic features of a virulent porcine deltacoronavirus strain.
    J Virol. 2024 Jul 16:e0064524. doi: 10.1128/jvi.00645.
    >> Share

  93. RICHARDSON SI, Mzindle N, Motlou T, Manamela NP, et al
    SARS-CoV-2 BA.4/5 infection triggers more cross-reactive FcgammaRIIIa signaling and neutralization than BA.1, in the context of hybrid immunity.
    J Virol. 2024 Jul 2:e0067824. doi: 10.1128/jvi.00678.
    >> Share

    June 2024
  94. ZHU J, Wang Z, Li Y, Zhang Z, et al
    Trimerized S expressed by modified vaccinia virus Ankara (MVA) confers superior protection against lethal SARS-CoV-2 challenge in mice.
    J Virol. 2024 Jun 14:e0052124. doi: 10.1128/jvi.00521.
    >> Share

  95. BOOPATHY AV, Nekkalapudi A, Sung J, Schulha S, et al
    Flt3 agonist enhances immunogenicity of arenavirus vector-based simian immunodeficiency virus vaccine in macaques.
    J Virol. 2024 Jun 3:e0029424. doi: 10.1128/jvi.00294.
    >> Share

  96. LU J, Liu J, Wu Y, He X, et al
    A full-length glycoprotein mRNA vaccine confers complete protection against severe fever with thrombocytopenia syndrome virus, with broad-spectrum protective effects against bandaviruses.
    J Virol. 2024 Jun 3:e0076924. doi: 10.1128/jvi.00769.
    >> Share

    May 2024
  97. CARTER DM, Darby CA, Lefoley BC, Crevar CJ, et al
    Correction for Carter et al., "Design and Characterization of a Computationally Optimized Broadly Reactive Hemagglutinin Vaccine for H1N1 Influenza Viruses".
    J Virol. 2024 May 31:e0181323. doi: 10.1128/jvi.01813.
    >> Share

  98. DOETS K, Pijlman GP
    Subgenomic flavivirus RNA as key target for live-attenuated vaccine development.
    J Virol. 2024 May 29:e0010023. doi: 10.1128/jvi.00100.
    >> Share

  99. HASHIZUME M, Takashima A, Iwasaki M
    An mRNA-LNP-based Lassa virus vaccine induces protective immunity in mice.
    J Virol. 2024 May 20:e0057824. doi: 10.1128/jvi.00578.
    >> Share

    April 2024
  100. THORESEN D, Matsuda K, Urakami A, Ngwe Tun MM, et al
    A tetravalent dengue virus-like particle vaccine induces high levels of neutralizing antibodies and reduces dengue replication in non-human primates.
    J Virol. 2024 Apr 22:e0023924. doi: 10.1128/jvi.00239.
    >> Share

  101. FAN Y-C, Chen J-M, Chen Y-Y, Ke Y-D, et al
    Epitope(s) involving amino acids of the fusion loop of Japanese encephalitis virus envelope protein is(are) important to elicit protective immunity.
    J Virol. 2024;98:e0177323.
    >> Share

  102. PEREZ DR
    A devastating blow: personal reflections on Argentina's scientific decline.
    J Virol. 2024 Apr 16:e0054924. doi: 10.1128/jvi.00549.
    >> Share

  103. ISHIMARU H, Nishimura M, Shigematsu H, Marini MI, et al
    Epitopes of an antibody that neutralizes a wide range of SARS-CoV-2 variants in a conserved subdomain 1 of the spike protein.
    J Virol. 2024 Apr 16:e0041624. doi: 10.1128/jvi.00416.
    >> Share

  104. TANG X, Li S, Zhou J, Bian X, et al
    Recombinant bivalent subunit vaccine combining truncated VP4 from P[7] and P[23] induces protective immunity against prevalent porcine rotaviruses.
    J Virol. 2024 Apr 9:e0021224. doi: 10.1128/jvi.00212.
    >> Share

  105. QUADIRI A, Prakash S, Dhanushkodi NR, Singer M, et al
    Therapeutic prime/pull vaccination of HSV-2-infected guinea pigs with the ribonucleotide reductase 2 (RR2) protein and CXCL11 chemokine boosts antiviral local tissue-resident and effector memory CD4(+) and CD8(+) T cells and protects against recurrent
    J Virol. 2024 Apr 8:e0159623. doi: 10.1128/jvi.01596.
    >> Share

  106. MANTEL N, Piras-Douce F, Chautard E, Marcos-Lopez E, et al
    Cynomolgus macaques as a translational model of human immune responses to yellow fever 17D vaccination.
    J Virol. 2024 Apr 3:e0151623. doi: 10.1128/jvi.01516.
    >> Share

  107. BRUNET J, Choucha Z, Gransagne M, Tabbal H, et al
    A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: candidate selection in a preclinical murine model.
    J Virol. 2024 Apr 2:e0169323. doi: 10.1128/jvi.01693.
    >> Share

  108. NAMBULLI S, Escriou N, Rennick LJ, Demers MJ, et al
    A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: protection of African green monkeys from COVID-19 disease.
    J Virol. 2024 Apr 2:e0176223. doi: 10.1128/jvi.01762.
    >> Share

  109. ZHU Z, Han Y, Gong M, Sun B, et al
    Establishment of replication-competent vesicular stomatitis virus recapitulating SADS-CoV entry.
    J Virol. 2024 Apr 1:e0195723. doi: 10.1128/jvi.01957.
    >> Share

    March 2024
  110. WU K, Hou YJ, Makrinos D, Liu R, et al
    Characterization of humoral and cellular immunologic responses to an mRNA-based human cytomegalovirus vaccine from a phase 1 trial of healthy adults.
    J Virol. 2024 Mar 25:e0160323. doi: 10.1128/jvi.01603.
    >> Share

  111. NUNBERG JH, Westover JB, York J, Jung KH, et al
    Restoration of virulence in the attenuated Candid#1 vaccine virus requires reversion at both positions 168 and 427 in the envelope glycoprotein GPC.
    J Virol. 2024 Mar 20:e0011224. doi: 10.1128/jvi.00112.
    >> Share

  112. MAI F, Bergmann W, Reisinger EC, Muller-Hilke B, et al
    The varying extent of humoral and cellular immune responses to either vector- or RNA-based SARS-CoV-2 vaccines persists for at least 18 months and is independent of infection.
    J Virol. 2024 Mar 19:e0191223. doi: 10.1128/jvi.01912.
    >> Share

    February 2024
  113. GEORGANA I, Scutts SR, Gao C, Lu Y, et al
    Filamin B restricts vaccinia virus spread and is targeted by vaccinia virus protein C4.
    J Virol. 2024 Feb 27:e0148523. doi: 10.1128/jvi.01485.
    >> Share

  114. JOSHI VR, Claiborne DT, Pack ML, Power KA, et al
    A VRC13-like bNAb response is associated with complex escape pathways in HIV-1 envelope.
    J Virol. 2024 Feb 27:e0172023. doi: 10.1128/jvi.01720.
    >> Share

  115. KATAYAMA M, Murakami S, Ishida H, Matsugo H, et al
    Antigenic commonality and divergence of hemagglutinin-esterase-fusion protein among influenza D virus lineages revealed using epitope mapping.
    J Virol. 2024 Feb 12:e0190823. doi: 10.1128/jvi.01908.
    >> Share

  116. SHINGAI M, Iida S, Kawai N, Kawahara M, et al
    Extraction of the CDRH3 sequence of the mouse antibody repertoire selected upon influenza virus infection by subtraction of the background antibody repertoire.
    J Virol. 2024 Feb 7:e0199523. doi: 10.1128/jvi.01995.
    >> Share

  117. LI H, Sun H, Tao M, Han Q, et al
    Recombinant parainfluenza virus 5 expressing clade 2.3.4.4b H5 hemagglutinin protein confers broad protection against H5Ny influenza viruses.
    J Virol. 2024 Feb 2:e0112923. doi: 10.1128/jvi.01129.
    >> Share

  118. HSIEH M-S, Hsu C-W, Liao H-C, Lin C-L, et al
    SARS-CoV-2 spike-FLIPr fusion protein plus lipidated FLIPr protects against various SARS-CoV-2 variants in hamsters.
    J Virol. 2024 Feb 1:e0154623. doi: 10.1128/jvi.01546.
    >> Share

    January 2024
  119. ROWE T, Davis W, Wentworth DE, Ross T, et al
    Differential interferon responses to influenza A and B viruses in primary ferret respiratory epithelial cells.
    J Virol. 2024 Jan 31:e0149423. doi: 10.1128/jvi.01494.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016